Some of the biggest questions hovering over pharma this year have been answered. We now know who the next U.S. president will be. Pharma companies are revealing plans to fill revenue gaps threatened by upcoming patent cliffs. And the biotech market has largely stabilized after a roller coaster couple of years. 

But now, of course, a new uncertainty has emerged — namely, how the incoming Trump administration and the president-elect’s nominees for key leadership positions could impact healthcare policy during his term. 

Our most-read stories of the year reflect these major shifts in the political and regulatory landscape along with other key trends in pharma. While pharma leaders navigate a tight financial landscape, public perception challenges have resurfaced now that the pandemic-era halo effect has faded and health equity comes into focus. 

As we round the corner into 2025, our coverage will continue to track these critical storylines while, of course, showcasing the thought leaders, innovations and industry strategies poised to shape pharma in the years to come. 

Here are our most popular articles of 2024.